Ready-to-Use Pre-Filled Syringe Formulations
•16 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (16)
| Company | Market Cap | Price |
|---|---|---|
|
JNJ
Johnson & Johnson
TREMFYA subcutaneous induction and other injectables often utilize ready-to-use pre-filled syringe formats.
|
$454.86B |
$188.88
-0.09%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
EYLEA HD enhancements include ready-to-use pre-filled syringe formulations.
|
$69.08B |
$651.52
-0.39%
|
|
ARGX
argenx SE
VYVGART Hytrulo is delivered via Ready-to-Use Pre-Filled Syringe Formulations for self-injection.
|
$48.94B |
$818.45
-0.23%
|
|
STVN
Stevanato Group S.p.A.
Offers Ready-to-Use Pre-Filled Syringe Formulations, aligning with RTU syringe/ cartridge packaging for biologics.
|
$7.64B |
$25.42
+1.92%
|
|
ALKS
Alkermes plc
Ready-to-use pre-filled syringe formulations for injectable therapies.
|
$5.07B |
$30.70
-0.39%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
DHE autoinjector and 505(b)(2) injectable programs imply Ready-to-Use Pre-Filled Syringe Formulations.
|
$3.39B |
$10.82
+8.20%
|
|
ZLAB
Zai Lab Limited
Ready-to-Use pre-filled syringe formulations for convenient on-market delivery (e.g., VYVGART PFS).
|
$2.83B |
$26.12
+2.37%
|
|
ANIP
ANI Pharmaceuticals, Inc.
Ready-to-Use Pre-Filled Syringe Formulations for Cortrophin Gel indicate a move toward convenient administration formats.
|
$1.96B |
$90.62
-1.42%
|
|
CLDX
Celldex Therapeutics, Inc.
Celldex utilizes Ready-to-Use Pre-Filled Syringe Formulations for administering therapies in trials.
|
$1.77B |
$26.70
+2.69%
|
|
XERS
Xeris Biopharma Holdings, Inc.
Ready-to-Use Pre-Filled Syringe Formulations are a key product format used by Xeris's injectable therapies.
|
$1.55B |
$9.69
-0.21%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Potentially applicable to ready-to-administer injectable formulations in pipeline; aligns with pre-filled syringe formats.
|
$1.20B |
$25.52
+3.49%
|
|
LFCR
Lifecore Biomedical, Inc.
Ready-to-Use Pre-Filled Syringe Formulations are part of Lifecore's injectable drug-delivery offerings.
|
$266.21M |
$7.18
+1.13%
|
|
HRTX
Heron Therapeutics, Inc.
Development of Ready-to-Use Pre-Filled Syringe Formulations for ZYNRELEF indicates a packaging/formulation-focused product variant.
|
$176.97M |
$1.15
+0.88%
|
|
CPIX
Cumberland Pharmaceuticals Inc.
Ready-to-Use Pre-Filled Syringe Formulations represent a packaging/delivery format aspect of CPIX's drug portfolio.
|
$44.73M |
$2.99
-6.85%
|
|
TLPH
Talphera, Inc.
Talphera is developing ready-to-use pre-filled syringe formulations (e.g., Fedsyra) for nafamostat-based therapies.
|
$27.47M |
$1.31
+5.65%
|
|
SCNX
Scienture Holdings, Inc.
SCNX references Ready-to-Use Pre-Filled Syringe Formulations for injectable therapies, a product-format related tag.
|
$10.18M |
$0.78
+1.15%
|
Loading company comparison...
Loading industry trends...
Loading research report...
